Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 2, 25 | -0.95 Decreased by -20.21% | -0.76 Decreased by -25.00% |
| Mar 24, 25 | -0.81 Decreased by N/A% | -1.29 Increased by +36.88% |
| Nov 7, 24 | -0.72 Decreased by -12.50% | -0.79 Increased by +8.86% |
| Sep 9, 24 | -1.01 Decreased by -40.28% | -0.97 Decreased by -4.12% |
| Apr 2, 24 | -0.79 | -0.60 Decreased by -31.72% |
| Feb 6, 24 | 0.00 | -0.92 Increased by +100.00% |
| Nov 29, 23 | -0.64 | -0.64 |
| Sep 21, 23 | -0.72 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by -100.00% | -52.37 M Increased by +45.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 4.01 M Increased by +78.20% | -47.30 M Increased by +8.95% | Decreased by -1.18 K% Increased by +48.91% |
| Jun 30, 24 | 3.39 M Increased by +N/A% | -40.82 M Decreased by N/A% | Decreased by -1.20 K% - |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -42.87 M Decreased by -6.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.33 M Increased by +N/A% | -95.79 M Decreased by N/A% | Decreased by -4.12 K% - |
| Jun 30, 23 | 2.25 M Increased by +0.90% | -51.95 M Decreased by -75.80% | Decreased by -2.31 K% Decreased by -74.23% |
| Mar 31, 23 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |
| Dec 31, 22 | 2.25 M Increased by +N/A% | -40.29 M Decreased by -143.74% | Decreased by -1.79 K% - |